Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid MalignanciesDavid Olmos, Sarah P. Blagden, Douglas S. Barker et al.|Clinical Cancer Research|2011Cited by 168
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcomeJia Huang, Yan Degenhardt, Yan Wang et al.|Genes Chromosomes and Cancer|2011Cited by 107